Vcanbio Cell & Gene Engineering Corp Ltd (600645) - Total Liabilities

Latest as of March 2026: CN¥1.50 Billion CNY ≈ $219.17 Million USD

Based on the latest financial reports, Vcanbio Cell & Gene Engineering Corp Ltd (600645) has total liabilities worth CN¥1.50 Billion CNY (≈ $219.17 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Vcanbio Cell & Gene Engineering Corp Ltd equity growth rate to track the company's year-over-year net asset growth rate.

Vcanbio Cell & Gene Engineering Corp Ltd - Total Liabilities Trend (1992–2025)

This chart illustrates how Vcanbio Cell & Gene Engineering Corp Ltd's total liabilities have evolved over time, based on quarterly financial data. See 600645 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Vcanbio Cell & Gene Engineering Corp Ltd Competitors by Total Liabilities

The table below lists competitors of Vcanbio Cell & Gene Engineering Corp Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Morgan Stanley Direct Lending Fund NYSE:MSDL	USA	$2.13 Billion
ROMANDE ENERGIE SA SW:REHN	Switzerland	CHF701.99 Million
Huizhou Speed Wireless Technology Co Ltd SHE:300322	China	CN¥2.41 Billion
Batisoke Soke Cimento Sanayi TAS IS:BSOKE	Turkey	TL3.94 Billion
Forbo Holding AG SW:FORN	Switzerland	CHF349.90 Million
ACV Auctions Inc. NASDAQ:ACVA	USA	$732.05 Million
Kailuan Energy Chemical Co Ltd SHG:600997	China	CN¥11.39 Billion
Energizer Holdings Inc NYSE:ENR	USA	$4.23 Billion

Liability Composition Analysis (1992–2025)

This chart breaks down Vcanbio Cell & Gene Engineering Corp Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600645 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.88	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.40	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vcanbio Cell & Gene Engineering Corp Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vcanbio Cell & Gene Engineering Corp Ltd (1992–2025)

The table below shows the annual total liabilities of Vcanbio Cell & Gene Engineering Corp Ltd from 1992 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥1.54 Billion ≈ $224.98 Million	-3.30%
2024-12-31	CN¥1.59 Billion ≈ $232.65 Million	-1.42%
2023-12-31	CN¥1.61 Billion ≈ $236.00 Million	-1.12%
2022-12-31	CN¥1.63 Billion ≈ $238.66 Million	+8.69%
2021-12-31	CN¥1.50 Billion ≈ $219.59 Million	+8.96%
2020-12-31	CN¥1.38 Billion ≈ $201.53 Million	-3.55%
2019-12-31	CN¥1.43 Billion ≈ $208.93 Million	-2.14%
2018-12-31	CN¥1.46 Billion ≈ $213.50 Million	+6.84%
2017-12-31	CN¥1.37 Billion ≈ $199.82 Million	+9.08%
2016-12-31	CN¥1.25 Billion ≈ $183.18 Million	+10.35%
2015-12-31	CN¥1.13 Billion ≈ $165.99 Million	-10.01%
2014-12-31	CN¥1.26 Billion ≈ $184.46 Million	+52.82%
2013-12-31	CN¥824.89 Million ≈ $120.71 Million	-13.34%
2012-12-31	CN¥951.88 Million ≈ $139.29 Million	+64.49%
2011-12-31	CN¥578.70 Million ≈ $84.68 Million	+9.69%
2010-12-31	CN¥527.56 Million ≈ $77.20 Million	+14.51%
2009-12-31	CN¥460.71 Million ≈ $67.42 Million	+16.51%
2008-12-31	CN¥395.43 Million ≈ $57.86 Million	-1.94%
2007-12-31	CN¥403.23 Million ≈ $59.01 Million	+1.99%
2006-12-31	CN¥395.35 Million ≈ $57.85 Million	+22.46%
2005-12-31	CN¥322.85 Million ≈ $47.24 Million	+29.68%
2004-12-31	CN¥248.95 Million ≈ $36.43 Million	-8.16%
2003-12-31	CN¥271.07 Million ≈ $39.67 Million	+29.33%
2002-12-31	CN¥209.59 Million ≈ $30.67 Million	-42.94%
2001-12-31	CN¥367.31 Million ≈ $53.75 Million	+50.29%
2000-12-31	CN¥244.41 Million ≈ $35.76 Million	-0.34%
1999-12-31	CN¥245.24 Million ≈ $35.89 Million	-4.46%
1998-12-31	CN¥256.69 Million ≈ $37.56 Million	-19.66%
1997-12-31	CN¥319.51 Million ≈ $46.75 Million	+76.50%
1996-12-31	CN¥181.03 Million ≈ $26.49 Million	-3.57%
1995-12-31	CN¥187.72 Million ≈ $27.47 Million	+70.80%
1994-12-31	CN¥109.91 Million ≈ $16.08 Million	+145.09%
1993-12-31	CN¥44.85 Million ≈ $6.56 Million	+24.05%
1992-12-31	CN¥36.15 Million ≈ $5.29 Million	--

About Vcanbio Cell & Gene Engineering Corp Ltd

SHG:600645 China Biotechnology

Market Cap

$1.29 Billion

CN¥8.83 Billion CNY

Market Cap Rank

#7799 Global

#1759 in China

Share Price

CN¥18.87

Change (1 day)

-0.42%

52-Week Range

CN¥16.74 - CN¥32.94

All Time High

CN¥68.93